Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery

Xingxing Wang1†, Hao Wang2†, Haixing Wang1, Jie Huang1, Xin Wang1, Zhengzeng Jiang1, Lijie Tan2, Dongxian Jiang1* and Yingyong Hou1,3,4*

Abstract

Background: We assessed visual residual tumour cells (VRTC) with both Becker’s tumour regression grading (TRG) system and Japanese TRG system in esophageal squamous cell carcinoma (ESCC) patients treated with neoadjuvant therapy followed by surgery.

Methods: We compared Becker system and Japanese system in 175 ESCC patients treated between 2009 and 2015.

Results: According to Becker system, the 5-year DFS/DSS rates were 70.0%/89.3, 53.8%/56.7, 43.0%/49.0, and 42.4%/39.1% for TRG 1a (VRTC 0), TRG 1b (1–10%), TRG 2 (11–50%), and TRG 3 (> 50%). According to Japanese system, the rates were 38.8%/34.1, 49.5%/58.7, 50.2%/49.0 and 70.0%/89.3% for Grade 0-1a (VRTC>66.6%), Grade 1b (33.3–66.6%), Grade 2 (1–33.3%) and Grade 3 (0). TRG according to two systems significantly discriminate the patients’ prognosis. TRG according to Becker system (HR 2.662, 95% CI 1.151–6.157), and lymph node metastasis (HR 2.567, 95% CI 1.442–4.570) were independent parameters of DSS.

Conclusions: Both Becker and Japanese system had their advantage in risk stratification of these ESCC patients. It was speculated that dividing 1–10% VRTC into a group might contribute to independently prognostic significance of Becker’s TRG system. Therefore, in addition to TRG of different systems, the percentage of VRTC might be recommended in the pathologic report, which could make the results more comparable among different researches, and more understandable for oncologists in the clinical practice.

Keywords: Neoadjuvant therapy, Esophageal squamous cell carcinoma (ESCC), Visual residual tumour cells (VRTC), Tumour regression grading (TRG), Lymph node metastases (LNM)
Background
Esophageal cancer (EC) is the ninth most common cancer and the sixth most common cause of cancer death globally [1]. Chinese population-based studies have shown approximately 477,900 persons receive a diagnosis of EC, and 375,000 persons died of EC in 2015, ranking it as the third most commonly diagnosed cancer and the fourth leading causes of cancer death in China [2]. Surgical resection has been the mainstay of treatment for EC. However, the majority of patients with locally advanced EC who undergo surgical resection eventually develop local recurrence or distant metastasis, and the 5-year survival rate is only 5–34% [3]. In an attempt to improve survival, many investigators around the world have assessed multidisciplinary strategies. The preoperative neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) combined with surgery have gained more attention in the treatment of locally advanced EC [4, 5]. Several studies have shown that neoadjuvant therapy (nCT or nCRT) followed by surgery significantly improves disease free survival (DFS) and overall survival (OS) compared with surgery alone, making it standard therapy for locally advanced EC [6–9]. Accumulating evidence indicates that the histological evaluation of the regression response to nCT or nCRT is the most important predictor of survival [5, 10].

Tumour regression grade (TRG) system referring to the amount of therapy-induced fibrosis in relation to residual tumour after nCRT has been initially developed by Mandard and coworkers [11]. However, the reproducibility and prognostic value of this system has been challenged because of the difficulties in the assessment of the relative amount of fibrosis [12]. Then the quantitative analysis of regression response through the estimated percentage of visual residual tumour cell (VRTC) in relation to the previous tumour site has been proposed. At present, there are several classification systems (2 to 5 grades) available in the literature, with the cut-off value of 1, 10 and 50% [13–18]. Among the systems, a modification of 4-tiered Becker system not only resulted in statistically superior rates for interobserver agreement but also in achievement of a better prognostic impact in many reports [19]. Besides, TRG system with cutoff value of 1/3 and 2/3, according to Japanese Classification of Esophageal Cancer (JEC) [20, 21]. The larger retrospective studies found that the Japanese system was also simple, reproducible and prognosis-associated [22, 23]. At present, there was no study to compare the application of the 2 major approaches (Becker system and Japanese system) for assessment of VRTC in ESCC after neoadjuvant therapy.

In the ESCC patients with neoadjuvant therapy, we compared the Becker system and Japanese system for assessment of VRTC, and tried to explore the prognostic factors.

Methods
Patients
This study was based on a retrospective review of 175 patients who underwent surgical resection following 2 to 3 cycles of neoadjuvant chemotherapy (nCT) or neoadjuvant chemoradiotherapy (nCRT) for ESCC, between November 2009 and December 2015 at Zhongshan Hospital, Fudan University, Shanghai, China. They were diagnosed as locally advanced-stage disease (clinical T3–4), using endoscopy, computed tomography (CT) of the chest and abdomen, endoscopic ultrasound, and positron emission tomography (PET), and required neoadjuvant treatment as first-line treatment prior to surgical resection. Informed consents were obtained from all patients. This study was approved by the Institutional Review Board of our hospital (B2016–135) and was performed according to the ethical principles of the Declaration of Helsinki.

The patients were followed up routinely in outpatients, every 3 months in the first year and every 6 months in the second year, followed by annual evaluations. Patients who did not go to our hospital were contacted by telephone to obtain follow-up data.

Pathological analysis
For specimens with neoadjuvant therapy in our hospital, all the suspected area of tumors were embedded and sectioned after the macroscopic examination, and all slides were evaluated by pathologists at once. For this study, all 175 surgically resected ESCC specimens were systematically reevaluated histopathologically by two experienced gastrointestinal pathologists. The histopathological review was undertaken with the pathologists blinded to the treatment results. The original tumour area was identified by signs of tumour regression changes, such as marked fibrosis, necrosis, flattening of the mucosa, or the presence of foreign body giant cell reaction. The extent of VRTC was assessed semiquantitatively, based on the estimated percentage of cancer in relation to the total cancer area [19–21]. With the repeated observation of tumour regression changes and training in evaluating standard, a consistency of 99% was achieved by the two pathologists. So far, several TRG systems have been used to assess the pathologic response to preoperative neoadjuvant therapy. In our study, the extent of VRTC was divided into four categories according to Becker regression criteria [19] or the Japanese Classification of Esophageal Cancer (JEC) [20, 21].

Other clinicopathologic characteristics were also recorded, including age, gender, tumour location, tumour grade, tumour size (measured during the pathological...
sampling), lymphovascular invasion, perineural growth, number of positive lymph nodes (LN), and the type of neoadjuvant.

Statistical analysis
Categorical data were analyzed using χ² test or Fisher’s exact test. Survival curves were estimated using the Kaplan–Meier method and were compared using the log-rank test. Overall survival (OS) was defined as the period from the date of surgery until the last confirmed date of survival or the date of death. Disease specific survival (DSS) was defined as the period from the date of surgery until the date of death, because of ESCC. Disease free survival (DFS) was defined as the period from the date of surgery until the date of disease progression or the date of death, because of ESCC. The Cox proportional hazard model was used to examine the association between clinicopathological factors and survival, to identify independent prognostic factors. Hazard rates (HRs) with its 95% confidence intervals (95% CIs) were used to determine the effect of each variable on outcome. Statistical analysis was performed using the SPSS software, version 21.0 (SPSS Inc., Chicago, IL), with statistical significance being considered with \( P < 0.05 \) (two-sided).

Results
Patient and general pathological characteristics
The clinical and pathological characteristics of the 175 patients are summarized in Table 1. There were 148 male and 27 female patients with a mean age of 59.8 (range 41–73) years. Tumours were most often located in mid-esophagus (\( n = 82 \)) compared with the upper third (\( n = 29 \)) or the lower third (\( n = 64 \)). The mean tumour length was 2.9 (range 0.3–9.0) cm. One hundred eight patients (61.7%) were treated with preoperative chemotherapy, whereas 67 (38.3%) patients were treated with preoperative chemoradiotherapy. No residual tumour was found in 26 patients. Vessel and nerve invasion were identified in 57 (32.6%) and 56 (32.0%) tumours, respectively. In 26 patients. Vessel and nerve invasion were identified in 57 (32.6%) and 56 (32.0%) tumours, respectively. In 83 patients who had positive LN status, 51 patients (61.5%) had 1–2 positive LN, 23 patients (27.7%) had 3–6 positive LNs, and 9 patients (10.8%) had more than 6 positive LNs.

Effect of neoadjuvant therapy on ESCC
TRG system of Becker or Japanese Esophageal Cancer Association was widely accepted in western country or Japan, which was used in our study, separately. According to the Becker system, there were 26 cases (14.9%) of TRG 1a, 36 cases (20.6%) of TRG 1b, 33 cases (18.9%) of TRG 2, and 80 cases (45.7%) of TRG 3 (Fig. 1). Namely, 62 tumours (35.4%) showed a histopathological response of TRG 1a or 1b, whereas the remainder showed minor or no response (Table 1). According to the Japanese system, there were 64 cases (36.6%) of Grade 0-1a, 28 cases (16.0%) of Grade 1b, 57 cases (32.6%) of Grade 2, and 26 cases (14.9%) of Grade 3. Namely, 83 tumours (47.4%) showed a histopathological response of Grade 2 or 3, whereas the remainder showed minor or no response (Table 1).

Table 1 depicts the associations between TRG and different pathological variables. According to Becker and Japanese system, we found that more VRTC (reflecting poor response following neoadjuvant treatment) were significantly associated with longer tumour length, poorly differentiated tumour, lymphovascular invasion, perineural invasion, lymph node metastases (LNM) and single neoadjuvant treatment (Chemotherapy alone) \( (P < 0.05) \) (Table 1).

Survival analysis
The median follow-up duration was 24.0 months (range, 2 to 86 months). At the time of analysis, 70 patients (40.0%) had disease progression and 59 patients (33.7%) had died of esophageal cancer. At total, 68 patients (38.9%) died. The 1-, 2-, 3-, and 5-year postoperative DFS rates for the patients in this study were 82.8, 63.9, 57.6, and 50.3%, respectively. The 1-, 2-, 3-, and 5-year postoperative DSS rates for the patients in this study were 91.0, 73.4, 60.9, and 51.0%, respectively. The 1-, 2-, 3-, and 5-year postoperative OS rates for the patients in this study were 88.8, 72.4, 56.9, and 45.6%, respectively.

Histopathological TRG as a prognostic factor
Histopathological TRG was found to be strongly associated with survival. When the patients were categorized according to Becker system (TRG 1a, TRG 1b, TRG 2, and TRG 3), the 5-year DFS rates were 70.0% (median time 72 months), 53.8% (non-reached), 43.0% (29 months), and 42.4% (32 months), 5-year DSS rates were 89.3% (median time non-reached), 56.7% (median time non-reached), 49.0% (34 months), and 39.1% (36 months), and the 5-year OS rates were 72.2% (median time 78 months), 50.0% (non-reached), 50.0% (34 months), and 34.1% (34 months), respectively. Significant differences in DFS and DSS were observed between patients with TRG 1a/1b and TRG2/3 (\( P < 0.05 \)) but not between patients with TRG1a and TRG1b (\( P > 0.05 \)) (Fig. 2). When the patients were categorized according to Japanese system (Grade 0-1a, Grade 1b, Grade 2 and Grade 3), the 5-year DFS rates were 38.8% (median time 32 months), 49.5% (36 months), 50.2% (non-reached) and 70.0% (72 months), the 5-year DSS rates were 34.1% (median time 36 months), 58.7% (non-reached), 49.0% (58 months) and 89.3% (non-reached), and the 5-year OS rates were 31.1% (median time 31 months), 52.8% (non-reached), 45.4% (58 months) and 72.2% (78 months), respectively. Significant differences in DSS
|                         | n      | Percent (%) | tumour regression grade (Becker) | tumour regression grade (Japan) |
|-------------------------|--------|-------------|----------------------------------|---------------------------------|
|                         |        |             | TRG 1a-1b | % | P value | Grade 2-3 | % | P value |
| Age                     |        |             |          |   |         |           |   |         |
| < 60                    | 80     | 45.7        | 24       | 30.0 | 0.168   | 34        | 42.5 | 0.231   |
| ≥ 60                    | 95     | 54.3        | 38       | 40.0 |         | 49        | 51.6 |         |
| Gender                  |        |             |          |   |         |           |   |         |
| Female                  | 27     | 15.4        | 11       | 40.7 | 0.530   | 13        | 48.1 | 0.935   |
| Male                    | 148    | 84.6        | 51       | 34.5 |         | 70        | 47.3 |         |
| Anatomic location       |        |             |          |   |         |           |   |         |
| Upper third             | 29     | 16.6        | 15       | 51.7 | 0.118   | 18        | 62.0 | 0.221   |
| Middle third            | 82     | 46.9        | 25       | 30.5 |         | 37        | 45.1 |         |
| Lower third             | 64     | 36.6        | 22       | 34.4 |         | 28        | 43.8 |         |
| Size                    |        |             |          |   |         |           |   |         |
| < 3 cm                  | 90     | 51.4        | 41       | 45.6 | 0.004   | 58        | 64.4 | < 0.001 |
| ≥ 3 cm                  | 85     | 48.6        | 21       | 24.7 |         | 25        | 29.4 |         |
| Lymphovascular invasion |        |             |          |   |         |           |   |         |
| Negative                | 118    | 67.4        | 59       | 50.0 | < 0.001 | 70        | 59.3 | < 0.001 |
| Positive                | 57     | 32.6        | 3        | 5.3  |         | 13        | 22.8 |         |
| Perineural growth       |        |             |          |   |         |           |   |         |
| Negative                | 119    | 68.0        | 58       | 48.7 | < 0.001 | 73        | 61.3 | < 0.001 |
| Positive                | 56     | 32.0        | 4        | 7.1  |         | 10        | 17.9 |         |
| Lymph-node metastasis   |        |             |          |   |         |           |   |         |
| Negative                | 92     | 52.6        | 46       | 50.0 | < 0.001 | 57        | 62.0 | < 0.001 |
| Positive                | 83     | 47.4        | 16       | 19.3 |         | 26        | 31.3 |         |
| ypN-stage               |        |             |          |   |         |           |   |         |
| ypN0                    | 92     | 52.6        | 46       | 50.0 | < 0.001 | 57        | 62.0 | < 0.001 |
| ypN1                    | 51     | 29.1        | 12       | 30.8 |         | 20        | 39.2 |         |
| ypN2                    | 23     | 13.1        | 4        | 17.4 |         | 6         | 26.1 |         |
| ypN3                    | 9      | 5.1         | 0        | 0    |         | 0         | 0    |         |
| Type of neoadjuvant     |        |             |          |   |         |           |   |         |
| Chemotherapy            | 108    | 61.7        | 23       | 21.3 | < 0.001 | 30        | 27.8 | < 0.001 |
| Chemoradiotherapy       | 67     | 38.3        | 39       | 58.2 |         | 53        | 79.1 |         |
| tumour regression grade (Becker) |    |             |          |   |         |           |   |         |
| TRG1a                   | 26     | 14.9        |          |     |         |           |   |         |
| TRG1b                   | 36     | 20.6        |          |     |         |           |   |         |
| TRG2                    | 33     | 18.9        |          |     |         |           |   |         |
| TRG3                    | 80     | 45.7        |          |     |         |           |   |         |
| tumour regression grade (Japan) |   |             |          |   |         |           |   |         |
| G0-1a                   | 64     | 36.6        |          |     |         |           |   |         |
| G1b                     | 28     | 16.0        |          |     |         |           |   |         |
| G2                      | 57     | 32.6        |          |     |         |           |   |         |
| G3                      | 26     | 14.9        |          |     |         |           |   |         |
were observed between patients with Grade 3 and those with Grade 0-1a, 2 and 3 ($P < 0.05$) (Fig. 3).

**Independent prognostic factors**

The univariate analysis showed a significant DFS difference in 5 factors: tumour grade, lymphovascular invasion, perineural growth, LNM, and TRG. The univariate analysis showed a significant DSS difference in 6 factors: tumour size, lymphovascular invasion, perineural growth, LNM, and TRG. The multivariate analysis identified that TRG (Becker system) (HR, 2.050; 95% CI, 1.084 to 3.878 for DFS) (HR, 2.367; 95% CI, 1.123 to 4.991 for DSS) was potentially independent factor of DFS and DSS. Beside TRG, LNM (HR, 1.770; 95% CI, 1.069 to 2.932 for DFS) (HR, 2.496; 95% CI, 1.416 to 4.402 for DSS) was also independent factor of DFS and DSS (Table 2).

**Discussion**

In the present study, we retrospectively analyzed the clinicopathological data and outcomes of 175 patients with ESCC who underwent nCT or nCRT followed by surgery and elucidated the relationships between the clinicopathological characteristics. We designed the current investigation specifically focusing on patients with ESCC, which is the most common histological subtype of EC, particularly in China [2]. To the best of our knowledge, less related study has been conducted in China.

**Neoadjuvant therapy**

Prior to the emergence of chemotherapy and radiotherapy, surgical resection had been the curative treatment of first choice in EC. At present, neoadjuvant therapy is used widely for patients with locally advanced EC. Evidence indicates that neoadjuvant therapy (nCT or nCRT) significantly improves survival in patients with locally advanced EC compared with surgery alone [4, 6, 7]. In our series, the 5-year survival rate was 45.6%. In our center, the 5-year survival rate was 39.7% for patients undergoing surgery alone [24]. Other results [25] showed significant 13% increase in 5-year survival for neoadjuvant therapy plus surgery as compared with surgery alone.

A reliable prognostic factor for ESCC patients undergoing neoadjuvant therapy is lacking. As preoperative neoadjuvant therapy has been used increasingly in the management of locally ESCC patients, the identification of potential prognostic parameters in these patients has recently gained momentum.

**Histopathological evaluation of tumour response**

Histopathological tumour response after neoadjuvant therapy is believed to be an important objective factor
and has been shown to have prognostic value in several studies [12–14, 26]. Response of the primary tumour can range from the absence of response to a total response with no VRTC. There is a consensus that the patients with pathologic complete response after neoadjuvant therapy benefit from these treatment modalities with 5-year survival rates up to 60% [25, 27, 28]. Partial tumour response is a matter of ongoing debate with controversial results from different trials [23, 29].

There are several classification systems available in the literature, with classification of responders varying from a 1 to 50% of VRTC [15, 30]. We present a brief review of the literature on classification systems used to assess the pathologic response to preoperative neoadjuvant therapy, and outline the most commonly used TRG systems, to assess if tumour regression does predict statistically significant improvement in OS and DFS.
Table 2: Univariate and multivariate analyses of factors associated with disease free survival, disease specific survival and overall survival

| Univariate analysis                                      | DFS (HR (95% CI), P value) | DSS (HR (95% CI), P value) | OS (HR (95% CI), P value) |
|----------------------------------------------------------|-----------------------------|-----------------------------|---------------------------|
| Age (< 60 VS. ≥60)                                       | 0.892 (0.556–1.433)        | 0.638                       | 0.716 (0.429–1.193)       | 0.2 | 0.666 (0.413–1.072) | 0.094 |
| Gender (Female VS. Male)                                 | 2.093 (0.956–4.582)        | 0.065                       | 1.768 (0.801–3.906)       | 0.158 | 2.104 (0.960–4.613) | 0.063 |
| Anatomic location (Upper VS. Middle VS. Lower third)     | 1.145 (0.819–1.601)        | 0.429                       | 1.224 (0.850–1.762)       | 0.277 | 1.049 (0.751–1.465) | 0.778 |
| Size (< 3 cm VS. ≥3 cm)                                  | 1.252 (0.779–2.013)        | 0.353                       | 1.700 (1.012–2.856)       | 0.045 | 1.719 (1.060–2.789) | 0.028 |
| Lymphovascular invasion (Negative VS. Positive)          | 1.748 (1.082–2.824)        | 0.023                       | 1.869 (1.119–3.121)       | 0.017 | 1.859 (1.152–2.998) | 0.011 |
| Perineural growth (Negative VS. Positive)                | 1.879 (1.157–3.052)        | 0.011                       | 2.280 (1.363–3.814)       | 0.002 | 2.051 (1.262–3.333) | 0.004 |
| Lymph-node metastasis (Negative VS. Positive)            | 2.127 (1.316–3.438)        | 0.002                       | 3.072 (1.787–5.281)       | < 0.001 | 2.680 (1.633–4.398) | < 0.001 |
| Type of neoadjuvant (Chemotherapy VS. Chemoradiotherapy) | 1.208 (0.745–1.959)        | 0.443                       | 1.244 (0.724–2.069)       | 0.46 | 1.379 (0.848–2.242) | 0.195 |
| Tumour regression grade- (Becker system) (TRG 1a+1b VS. TRG2+ 3) | 2.596 (1.462–4.607)        | 0.001                       | 3.366 (1.703–6.649)       | < 0.001 | 2.436 (1.371–4.328) | 0.002 |
| Tumour regression grade- (Japanese system) (G0-1a+1b VS. G2+ 3) | 1.863 (1.143–3.037)        | 0.013                       | 2.155 (1.256–3.697)       | 0.005 | 1.888 (1.152–3.094) | 0.012 |
| Multivariate analysis 1                                  |                            |                             |                           |
| Size (< 3 cm VS. ≥3 cm)                                  | –                           | –                           | 1.198 (0.697–2.059)       | 0.514 | 1.267 (0.763–2.104) | 0.36 |
| Lymphovascular invasion (Negative VS. Positive)          | 0.990 (0.865–1.699)        | 0.943                       | 0.835 (0.462–1.510)       | 0.551 | 0.966 (0.551–1.693) | 0.903 |
| Perineural growth (Negative VS. Positive)                | 1.356 (0.799–2.301)        | 0.259                       | 1.575 (0.900–2.758)       | 0.112 | 1.479 (0.869–2.516) | 0.149 |
| Lymph-node metastasis (Negative VS. Positive)            | 1.770 (1.069–2.932)        | 0.027                       | 2.496 (1.416–4.402)       | 0.002 | 2.217 (1.315–3.736) | 0.003 |
| Tumour regression grade- (Becker system) (TRG 1a+1b VS. TRG2+ 3) | 2.050 (1.084–3.878)        | 0.027                       | 2.367 (1.123–4.991)       | 0.024 | 1.662 (0.867–3.187) | 0.126 |
| Multivariate analysis 2                                  |                            |                             |                           |
| Size (< 3 cm VS. ≥3 cm)                                  | –                           | –                           | 1.190 (0.678–2.089)       | 0.545 | 1.275 (0.753–2.160) | 0.366 |
| Lymphovascular invasion (Negative VS. Positive)          | 1.096 (0.625–1.922)        | 0.749                       | 0.945 (0.516–1.733)       | 0.856 | 1.059 (0.600–1.871) | 0.842 |
| Perineural growth (Negative VS. Positive)                | 1.431 (0.832–2.460)        | 0.195                       | 1.674 (0.947–2.962)       | 0.076 | 1.546 (0.901–2.651) | 0.113 |
| Lymph-node metastasis (Negative VS. Positive)            | 1.826 (1.097–3.038)        | 0.020                       | 2.621 (1.482–4.637)       | 0.001 | 2.282 (1.352–3.850) | 0.002 |
| Tumour regression grade- (Japanese system) (G0-1a+1b VS. G2+ 3) | 1.378 (0.787–2.414)        | 0.262                       | 1.393 (0.736–2.638)       | 0.308 | 1.198 (0.660–2.174) | 0.552 |
TRG systems of Becker
Among these systems, Becker et al. categorized TRG into four grades (TRG1a, 0%, TRG1b, 1–10%, TRG2, 11–50% and TRG3, >50%), which reflected prognosis and survival in a more object manner and widely accepted in tumour regression evaluation [19]. A step-by-step increase in tumour regression should be paralleled by a step-by-step increase in survival, however, some authors have argued whether the prognosis of cases showing 1–10% VRTC is inferior than those of patients with 0% VRTC [15, 31–33].

We reported a 5-year DFS rates of 70.0%, a DSS rate of 89.3% and an OS rate of 72.2% in TRG1a, a 5-year DFS rates of 53.8%, a DSS rate of 56.7% and an OS rate of 50.0% in TRG1b, a 5-year DFS rates of 43.0%, a DSS rate of 49.0% and an OS rate of 50.0% in TRG2, and a 5-year DFS rates of 42.4%, a DSS rate of 39.1% and an OS rate of 34.1% in TRG3. TRG1a or TRG1b have been associated with a statistically significant survival benefit compared with other regression classes. However, no statistically significant difference could be detected between TRG1a (0% VRTC) and TRG1b (1–10% VRTC) in our patients. Consistent with our results, recently published data indicated that no statistically significant difference could be detected between pathologic complete remission and microscopic residual disease in patients with EC, and TRG 1a-1b showed a statistically significant survival benefit compared with other regression classes [31, 34, 35]. This has also been reported for patients with non-small cell lung cancer [36], rectal cancer [37], as well as locally advanced gastric cancer [19] treated with neoadjuvant therapy. In our study, multivariate analysis confirmed that TRG according to Becker system was a potentially independent prognostic factor.

TRG system of the Japanese classification of esophageal cancer
The TRG system of the Japanese Classification of Esophageal Cancer was widely used in Japanese ESCC specimens [23, 30, 38]. Given the same histological subtype in China, Japanese grading system was also evaluated in our study: G0-1a, more than 2/3 residual carcinoma, G1b, 1/3 to 2/3 residual carcinoma, G2, < 1/3 residual carcinoma and G3, 0% residual carcinoma [20, 21]. Our date demonstrated that OS was best for patients with G3 and worst for patients with G0-1a, but there was no statistical difference in survival between patients with G1b and G2, who were in an intermediate prognostic category. The system was not significantly associated with DFS and OS in our multivariate analysis.

Comparison between Becker and Japanese system
The main difference between Becker system and Japanese system was the classification of patients with minimal residual tumour (1–10% VRTC). Becker system divided these patients into TRG 1b, as an independent group, who had the similar 5-year survival rates as the whole cohort. Japanese system incorporated these patients into G2 (< 1/3 VRTC) [19–21]. Studies using clinical response classifications according to Japanese grading system might underestimate the number of patients (1–10% VRTC) with an impressive survival benefit. However, these studies distinguished the group with partial response (< 1/3 VRTC) and the group with less response (> 2/3 VRTC), which recognized more patients with a survival benefit [23]. With the comparison of the two systems, we believed that the percentage of VRTC could also be used in regular pathology report, which would make the further study understandable and comparable.

Conclusion
In this study, we concluded that TRG according to both Becker system and Japanese system had its advantage in risk stratification of ESCC patients undergoing neoadjuvant therapy plus surgery. Based on Becker system, TRG was potentially independent predictors of patient outcome, which was not found based on Japanese system. The classification of cases showing 1–10% VRTC made the grouping different. We would like to recommend not only TRG according to Becker’s, Japanese and other systems but also the percentage of VRTC should be reported in the pathology evaluation, which could make study results more comparable among different research groups, and more understandable for oncologists in the clinical practice. Our findings might represent a valuable addition to the current literature in light of the increasing histopathologic response evaluation of neoadjuvant therapy in ESCC.

Abbreviations
VRTC: Visual Residual Tumour Cells; TRG: Tumour regression grading; ESCC: Esophageal squamous cell carcinoma; LNM: Lymph node metastases; EC: Esophageal cancer; nCT: Neoadjuvant chemotherapy; nCRT: Neoadjuvant chemoradiotherapy; DFS: Disease free survival; DSS: Disease specific survival; OS: Overall survival; CT: Computed tomography; PET: Positron emission tomography; LN: Lymph nodes; HRs: Hazard rates

Acknowledgements
Not applicable.

Authors’ contributions
XW, HW1, HW2, JH, XW, ZJ, performed the research; LT, DJ, and YH designed the research study; XW, HW1 analysed the data; LT, DJ, and YH wrote the paper. No conflict of interest exits in the submission of this manuscript, and manuscript is approved by all authors for publication.

Funding
This work was supported by Shanghai Natural Science Foundation of China (No. 18ZR1406800) for collection, National Natural Science Foundation of China (No. 81702372) for analysis, and Shanghai Municipal Commission of Science and Technology (No. 19441904000), Shanghai Municipal Key Clinical Specialty (No. shslczbK01302), Shanghai Science and Technology Development
**References**

1. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. \[10.1016/j.jval.2019.03.004\]

2. Chen W, Zheng R, Baade PD, Zhang S, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):84–96.

3. Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, et al. Neoadjuvant concurrent chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet. 2012;380(9851):2389–96.

4. Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet (London, England). 2013;381(9864):400–02.

5. Mariette C, Robb WB, Piessen G, Adenis A. Neoadjuvant chemoradiation in resectable thoracic esophageal squamous cell carcinoma - a propensity score matched analysis. Eur J Cancer (Oxford, England : 1990). 2015;51:210–18.

6. van Hagen P, Hulshof MC, van Lanschot JJ, Henegouwen MI, et al. Preoperative chemoradiotherapy for oesophagogastric adenocarcinomas. Br J Cancer. 2014;110(7):1712–20.

7. Langer R, Ott K, Feith M, Lordick F, Sievert JR, Becker K. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Modern Pathol. 2009;22(12):1555–63.

8. Wu TT, Chirieac LR, Abraham SC, Krasinski AM, Wang H, Rashid A, et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol. 2007;31(1):58–64.

9. van Meerten E, Muller K, Tilanus HW, Siersma PD, Eijkenboom WM, van Dekken H, et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer – a phase II study. Br J Cancer. 2006;94(10):1389–94.

10. Schneider PM, Baldus SE, Metzger R, Kocher M, Bourgois R, Bollier W, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242(5):694–92.

11. Becker K, Mueller JD, Schumacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521–30.

12. van Hagen P, Hulshof MC, van Lanschot JJ, Henegouwen MI, et al. Neoadjuvant concurrent chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet. 2012;380(9851):2389–96.

13. Mariette C, Robb WB, Piessen G, Adenis A. Neoadjuvant chemoradiation in resectable thoracic esophageal squamous cell carcinoma - a propensity score matched analysis. Eur J Cancer (Oxford, England : 1990). 2015;51:210–18.

14. Holscher AH, Bollichewell E, Bogoevski O, Schmidt H, Semrau R, Izbicki JR. Prognostic impact of neoadjuvant chemoradiation in cT3 esophageal cancer - a propensity score matched analysis. Eur J Cancer (Oxford, England : 1990). 2014;50(17):2950–7.

15. Holscher AH, Bollichewell E, Bogoevski O, Schmidt H, Semrau R, Izbicki JR. Prognostic impact of neoadjuvant chemoradiation in cT3 esophageal cancer - a propensity score matched analysis. Eur J Cancer (Oxford, England : 1990). 2014;50(17):2950–7.

16. Holscher AH, Bollichewell E, Bogoevski O, Schmidt H, Semrau R, Izbicki JR. Prognostic impact of neoadjuvant chemoradiation in cT3 esophageal cancer - a propensity score matched analysis. Eur J Cancer (Oxford, England : 1990). 2014;50(17):2950–7.
carcinoma receiving preoperative chemoradiation. Cancer. 2005;103(7):1347–55.

33. Chao YK, Chuang WY, Chang HK, Tseng CK, Yeh CJ, Liu YH. Prognosis of patients with esophageal squamous cell carcinoma who achieve major histopathological response after neoadjuvant chemoradiotherapy. Eur J Surg Oncol. 2017;43(1):294–9.

34. Francis AM, Sepesi B, Correa AM, Blum MA, Erasmus JJ, Lee JH, et al. The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma. Ann Surg. 2013;258(1):500–7.

35. Noble F, Nolan L, Bateman AC, Byrne JP, Kelly JJ, Bailey IS, et al. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World J Gastroenterol. 2013;19(48):9282–93.

36. Thomas M, Rube C, Semik M, von Eff M, Freitag L, Macha HN, et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol. 1999;17(4):1185.

37. Ruo L, Tickoo S, Klimstra DS, Minsky BD, Saltz L, Mazumdar M, et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg. 2002;236(1):75–81.

38. Akutsu Y, Shuto K, Kono T, Usato M, Hoshino I, Shiratori T, et al. The number of pathologic lymph nodes involved is still a significant prognostic factor even after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. J Surg Oncol. 2012;105(8):756–60.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.